Jean Viallet
Geen lopende functies
Profiel
Jean Viallet worked as Director-Clinical Development & Medical Division at GSK Plc and Senior Director-Clinical Oncology at Sanofi-Synthelabo, Inc. She also served as Chief Development Officer at Cleveland BioLabs, Inc. from 2013 to 2014 and as Chief Medical Officer at Gemin X Pharmaceuticals US, Inc. from 2002 to 2010.
She held the position of Chief Medical Officer at Helomics Corp.
and Alethia Biotherapeutics, Inc. Dr. Viallet received her undergraduate and doctorate degrees from the University of Montréal.
Eerdere bekende functies van Jean Viallet
| Bedrijven | Functie | Einde |
|---|---|---|
| STATERA BIOPHARMA, INC. | Corporate Officer/Principal | 03-01-2014 |
Gemin X Pharmaceuticals US, Inc.
 Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Hoofd Techniek/Wetenschap/O&O | - |
| Sanofi-Synthelabo, Inc. | Corporate Officer/Principal | - |
Alethia Biotherapeutics, Inc.
 Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Hoofd Techniek/Wetenschap/O&O | - |
Helomics Corp.
 Helomics Corp. Medical/Nursing ServicesHealth Services Helomics Corp. provides cancer care development and treatment consulting services. Its products include chemoFx, biospeciFx, geneFx colon and geneFx lung. It also offers research and development services. The company was founded in 1995 and is headquartered in Pittsburgh, PA. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Jean Viallet
| University of Montréal | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| GSK PLC | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Gemin X Pharmaceuticals US, Inc.
Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Health Technology |
Helomics Corp.
Helomics Corp. Medical/Nursing ServicesHealth Services Helomics Corp. provides cancer care development and treatment consulting services. Its products include chemoFx, biospeciFx, geneFx colon and geneFx lung. It also offers research and development services. The company was founded in 1995 and is headquartered in Pittsburgh, PA. | Health Services |
Cleveland BioLabs, Inc.
 Cleveland BioLabs, Inc. Pharmaceuticals: MajorHealth Technology Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. It focuses on oncology and acute radiation syndrome. It offers Entolimod, Mobilan, CBL0137, and SA-702. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Buffalo, NY. | Health Technology |
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Health Technology |
| Sanofi-Synthelabo, Inc. | Health Technology |
